UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
20.34
-0.13 (-0.64%)
Nov 3, 2025, 1:30 PM EST - Market open
UroGen Pharma Stock Forecast
Stock Price Forecast
The 8 analysts that cover UroGen Pharma stock have a consensus rating of "Strong Buy" and an average price target of $28.5, which forecasts a 40.12% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $47.
Price Target: $28.5 (+40.12%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for UroGen Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 4 | 4 | 4 |
| Buy | 1 | 2 | 2 | 3 | 3 | 3 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +96.66% | Oct 27, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +22.91% | Oct 27, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +22.91% | Oct 3, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $36 | Buy | Initiates | $36 | +76.99% | Aug 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $50 → $40 | Strong Buy | Maintains | $50 → $40 | +96.66% | Aug 11, 2025 |
Financial Forecast
Revenue This Year
123.31M
from 90.40M
Increased by 36.41%
Revenue Next Year
268.86M
from 123.31M
Increased by 118.04%
EPS This Year
-3.22
from -2.96
EPS Next Year
-0.83
from -3.22
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 142.6M | 411.1M | |||
| Avg | 123.3M | 268.9M | |||
| Low | 101.3M | 220.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 57.7% | 233.3% | |||
| Avg | 36.4% | 118.0% | |||
| Low | 12.1% | 78.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.77 | 2.14 | |||
| Avg | -3.22 | -0.83 | |||
| Low | -3.38 | -2.13 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.